Brolucizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | VEGFA |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1531589-13-5 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C1164H1768N310O372S7 |
| Molar mass | 26.31 kDa |
Brolucizumab (INN) is a humanized monoclonal antibody designed for the treatment of wet age-related macular degeneration.[1][2]
This drug was developed by Alcon Laboratories, Inc.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Brolucizumab, American Medical Association.
- ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
This article is issued from Wikipedia - version of the 7/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.